Premium
Pharmacotherapies for Post‐Bariatric Weight Regain: Real‐World Comparative Outcomes
Author(s) -
Gazda Chellse L.,
Clark John D.,
Lingvay Ildiko,
Almandoz Jaime P.
Publication year - 2021
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1002/oby.23146
Subject(s) - medicine , weight loss , pharmacotherapy , body weight , weight gain , retrospective cohort study , surgery , obesity , urology
Objective This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods This is a retrospective analysis of 207 individuals treated for post‐bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non–glucagon‐like‐1 receptor agonist (GLP‐1‐RA)‐based weight‐loss pharmacotherapy (WLP) group, and a GLP‐1‐RA‐based WLP group (the latter two groups in conjunction with ILM). Results The percentage body weight loss was significantly different between groups after 3 months (1.4% vs. 2.2% vs. 4.5% [ P < 0.001] for ILM, non–GLP‐1‐RA‐based WLP, and GLP‐1‐RA‐based WLP groups, respectively), 6 months (0.8% vs. 2.9% vs. 6.7% [ P < 0.001]), and 9 months (−1.6% vs. 5.6% vs. 6.9% [ P = 0.007]). There was a significant difference in the percentage of individuals achieving ≥5% weight loss after 3, 6, and 9 months, with most occurring in the GLP‐1‐RA‐based WLP group. In a multiple regression analysis including bariatric surgery type, treatment group was the only significant predictor of percentage weight change. Conclusions GLP‐1‐RA‐based WLP therapies were found to be more effective for treating post‐bariatric weight regain than non–GLP‐1‐RA‐based WLP or ILM, regardless of surgery type.